Uninterrupted continuous glucose monitoring access is associated with a decrease in HbA1c in youth with type 1 diabetes and public insurance.


Journal

Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345

Informations de publication

Date de publication:
11 2020
Historique:
received: 08 05 2020
revised: 22 06 2020
accepted: 06 07 2020
pubmed: 19 7 2020
medline: 19 11 2021
entrez: 19 7 2020
Statut: ppublish

Résumé

Continuous glucose monitor (CGM) use is associated with improved glucose control. We describe the effect of continued and interrupted CGM use on hemoglobin A1c (HbA1c) in youth with public insurance. We reviewed 956 visits from 264 youth with type 1 diabetes (T1D) and public insurance. Demographic data, HbA1c and two-week CGM data were collected. Youth were classified as never user, consistent user, insurance discontinuer, and self-discontinuer. Visits were categorized as never-user visit, visit before CGM start, visit after CGM start, visit with continued CGM use, visit with initial loss of CGM, visit with continued loss of CGM, and visit where CGM is regained after loss. Multivariate regression adjusting for age, sex, race, diabetes duration, initial HbA1c, and body mass index were used to calculate adjusted mean and delta HbA1c. Adjusted mean HbA1c was lowest for the consistent user group (HbA1c 8.6%;[95%CI 7.9,9.3]). Delta HbA1c (calculated from visit before CGM start) was lower for visit after CGM start (-0.39%;[95%CI -0.78,-0.02]) and visit with continued CGM use (-0.29%;[95%CI -0.61,0.02]), whereas it was higher for visit with initial loss of CGM (0.40%;[95%CI -0.06,0.86]), visit with continued loss of CGM (0.46%;[95%CI 0.06,0.85]), and visit where CGM is regained after loss (0.57%;[95%CI 0.06,1.10]). Youth with public insurance using CGM have improved HbA1c, but only when CGM use is uninterrupted. Interruptions in use, primarily due to gaps in insurance coverage of CGM, were associated with increased HbA1c. These data support both initial and ongoing coverage of CGM for youth with T1D and public insurance.

Identifiants

pubmed: 32681582
doi: 10.1111/pedi.13082
pmc: PMC8103618
mid: NIHMS1694887
doi:

Substances chimiques

Glycated Hemoglobin A 0
Hypoglycemic Agents 0
Insulin 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1301-1309

Subventions

Organisme : NIDDK NIH HHS
ID : K12 DK122550
Pays : United States
Organisme : NIDDK NIH HHS
ID : R18 DK122422
Pays : United States

Informations de copyright

© 2020 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd.

Références

Diabet Med. 2018 Apr;35(4):419-429
pubmed: 29356074
Cost Eff Resour Alloc. 2011 Sep 14;9:13
pubmed: 21917132
Pediatr Diabetes. 2018 Oct;19 Suppl 27:302-325
pubmed: 30039513
Diabetes Care. 2019 Aug;42(8):1398-1405
pubmed: 31123155
J Pediatr. 2006 Oct;149(4):526-31
pubmed: 17011326
Diabetes Care. 2020 Jan;43(1):e1-e2
pubmed: 31672703
Pediatr Diabetes. 2019 Mar;20(2):217-225
pubmed: 30575237
Diabetes Technol Ther. 2020 Sep;22(9):645-650
pubmed: 31905008
Pediatr Diabetes. 2018 Nov;19(7):1271-1275
pubmed: 29923262
Diabetes Care. 2018 Jun;41(6):1227-1234
pubmed: 29650803
Diabetes Technol Ther. 2019 Feb;21(2):66-72
pubmed: 30657336
Diabetes Care. 2020 Jan;43(Suppl 1):S77-S88
pubmed: 31862750
Diabetes Technol Ther. 2013 Oct;15(10):855-8
pubmed: 23865840
Diabetes Technol Ther. 2020 Mar;22(3):169-173
pubmed: 31596132
Diabetes Technol Ther. 2018 Sep;20(9):632-634
pubmed: 30020810
Pediatrics. 2015 Mar;135(3):424-34
pubmed: 25687140
Diabetes Care. 2010 Jan;33(1):17-22
pubmed: 19837791
Diabetes Care. 2020 Jan;43(Suppl 1):S163-S182
pubmed: 31862756
Diabetes Technol Ther. 2020 Sep;22(9):674-680
pubmed: 31971451
Diabetes Care. 2018 Dec;41(12):2517-2525
pubmed: 30327359
Int J Endocrinol. 2019 Nov 3;2019:4649303
pubmed: 31781209
J Diabetes Sci Technol. 2017 May;11(3):484-492
pubmed: 28745093
Pediatr Diabetes. 2013 Sep;14(6):447-54
pubmed: 23469984
Diabetologia. 2012 Sep;55(9):2356-60
pubmed: 22733482

Auteurs

Ananta Addala (A)

Division of Pediatric Endocrinology, Stanford University, Stanford, California, USA.

David M Maahs (DM)

Division of Pediatric Endocrinology, Stanford University, Stanford, California, USA.
Stanford Diabetes Research Center, Stanford University, Stanford, California, USA.

David Scheinker (D)

Division of Pediatric Endocrinology, Stanford University, Stanford, California, USA.
Stanford Diabetes Research Center, Stanford University, Stanford, California, USA.
Department of Management Science and Engineering, Stanford University, Stanford, California, USA.

Solana Chertow (S)

School of Arts and Sciences, Washington University in St. Louis, St. Louis, Missouri, USA.

Brianna Leverenz (B)

Division of Pediatric Endocrinology, Stanford University, Stanford, California, USA.

Priya Prahalad (P)

Division of Pediatric Endocrinology, Stanford University, Stanford, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH